Fig. 3From: Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial groupTime course of the response, assessed by the Up/c in a first morning urine sample, in the 5 subjects who achieved a ≥50 % reduction in proteinuria in response to the experimental therapyBack to article page